Y Intercept Hong Kong Ltd Sells 53,169 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Y Intercept Hong Kong Ltd reduced its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 89.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 6,395 shares of the company’s stock after selling 53,169 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Kiniksa Pharmaceuticals International were worth $248,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth $20,349,000. Qube Research & Technologies Ltd increased its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after acquiring an additional 447,536 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 186.2% in the second quarter. Squarepoint Ops LLC now owns 416,572 shares of the company’s stock worth $11,527,000 after acquiring an additional 271,005 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the subject of several analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wedbush increased their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Finally, The Goldman Sachs Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $52.33.

Kiniksa Pharmaceuticals International Trading Down 2.2%

NASDAQ:KNSA opened at $42.58 on Friday. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of 94.62 and a beta of 0.06. The firm has a fifty day simple moving average of $41.80 and a two-hundred day simple moving average of $38.13. Kiniksa Pharmaceuticals International, plc has a 12 month low of $18.12 and a 12 month high of $45.50.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period last year, the company earned ($0.18) EPS. Equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,470 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $41.24, for a total value of $514,262.80. Following the transaction, the chief operating officer owned 22,714 shares in the company, valued at approximately $936,725.36. This represents a 35.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 42,841 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the sale, the chief financial officer owned 31,086 shares of the company’s stock, valued at approximately $1,289,758.14. This represents a 57.95% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 135,548 shares of company stock valued at $5,675,604. 53.48% of the stock is owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.